<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550573</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0657</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT03550573</nct_id>
  </id_info>
  <brief_title>3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy</brief_title>
  <acronym>3D-CMH</acronym>
  <official_title>3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic cardiomyopathy (HCM) is very common. The thickened heart muscle can disrupt the
      normal functioning of the heart's electrical system, resulting in fast or irregular
      heartbeats. Today, there are no reliable means to identify HCM patients at risk of sudden
      death. The CardioInsight™ has recently been developed by Medtronic for non-invasive advanced
      cardiac mapping system. The CardioInsight™ Noninvasive 3D Mapping System is a non-invasive
      mapping system that collects chest ECG signals and combines these signals with CT scan data
      to produce and display simultaneous, bi-atrial and biventricular, 3-D cardiac maps.

      It is a monocentric, prospective, comparative and analytical study. 20 HCM patients will be
      recruited in the National Reference Center for inherited cardiac diseases of Lyon. The
      3D-propagation maps of 10 well phenotyped and genotyped HCM patients with previous VF
      (ventricular fibrillation) will be compared to 10 HCM patients without previous VF.

      After consent signed, Holter ECG, scanner and CardioInsightTM 3D_ECG mapping will be planned
      in the month following the inclusion. 12-lead ECG, 24h holter ECG, cardiac scanner will be
      performed as standard procedure of each center in the current health care of the patient.

      The widespread screening of HCM patients with 3D high-density noninvasive mapping should
      improve the risk-benefit ratio of implantable defibrillator therapy. It is expected that more
      patients at risk will benefit from this device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of specific markers of risk of sudden death in HCM patients from the maps created by the combination of CT and signal data.</measure>
    <time_frame>Month 1</time_frame>
    <description>The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The use of the CardioInsight system is correlated with a CT scan.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>hypertrophic cardiomyopathy without sudden death history</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertrophic cardiomyopathy with sudden death history</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioInsight™ Noninvasive 3D Mapping System</intervention_name>
    <description>The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.
This exam will be performed only at baseline visit.</description>
    <arm_group_label>hypertrophic cardiomyopathy with sudden death history</arm_group_label>
    <arm_group_label>hypertrophic cardiomyopathy without sudden death history</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  HCM patient confirmed by echocardiogram.

          -  Patient who signed the consent.

          -  Patient benefiting from a social insurance system or a similar system

        Exclusion Criteria:

          -  pregnant women,

          -  left ventricular dilation (diastolic &gt;60 mm diameter) and/or left ventricular systolic
             dysfunction (LVEF &lt;55%),

          -  prior cardiac surgery,

          -  atrial fibrillation,

          -  renal disease (serum creatinine &gt;2.0 mg/dl),

          -  primary cardiac valve disease

          -  coronary artery disease

          -  Previous recent cardiac scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe CHEVALIER, MD PhD</last_name>
    <phone>472357027</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.chevalier@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie MOREL, CRA</last_name>
    <phone>472357027</phone>
    <phone_ext>+33</phone_ext>
    <email>elodie.morel01@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Chevalier, Pr</last_name>
    </contact>
    <contact_backup>
      <last_name>Elodie MOREL, CRA</last_name>
      <email>elodie.morel01@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertrophic cardiomyopathy</keyword>
  <keyword>sudden death</keyword>
  <keyword>3D mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

